Circulation of Influenza Virus in the 2015/2016 Epidemic Season in Poland: Serological Evaluation of Anti-hemagglutinin Antibodies
Overview
General Medicine
Affiliations
The diagnostic of influenza virus infections is possible using molecular biology methods as well as the analysis of anti-hemagglutinin (anti-HA) antibodies in the blood serum. The aim of this study was to determine the level of anti-HA antibodies in 7 age groups of patients during the 2015/2016 epidemic season in Poland. A total of 1050 serum samples were tested using the hemagglutination inhibition (HAI) assay. We confirmed the presence of anti-HA antibodies for the influenza virus strains: A/California/7/2009(H1N1)pdm09, A/Switzerland/9715293/2013(H3N2), and B/Phuket/3073/2013, which were the components of the influenza vaccine for the 2015/2016 epidemic season. The level of specific anti-HA antibodies was different in each age group. The geometric mean titers were highest at age 5-9 years, where the antibody protection level reached 61.3% against B/Phuket/3073/2013 and 52.7% for A/Switzerland/9715293/2013(H3N2) antigen. The antibody level amounted to 56.7% against for antigen B at age 45-64. In the remaining age groups, the protection levels for all hemagglutinin types did not exceed 50%. These findings confirm the urgent need to increase a persistently low influenza vaccination coverage in the Polish population, which may have had its part in the noticeable increase in the confirmed cases of influenza and influenza-like virus infection during the season.
Factors affecting the immunogenicity of influenza vaccines in human.
Xu Q, Wei H, Wen S, Chen J, Lei Y, Cheng Y BMC Infect Dis. 2023; 23(1):211.
PMID: 37024804 PMC: 10078025. DOI: 10.1186/s12879-023-08158-3.
Genetic variants in BAT2 are associated with immune responsiveness to influenza vaccination.
Wen S, Wei H, Li M, Zhong S, Cheng Y, Huang W Front Genet. 2023; 14:1059447.
PMID: 36845396 PMC: 9951381. DOI: 10.3389/fgene.2023.1059447.
Factors influencing the immunogenicity of influenza vaccines.
Wen S, Wu Z, Zhong S, Li M, Shu Y Hum Vaccin Immunother. 2021; 17(8):2706-2718.
PMID: 33705263 PMC: 8475607. DOI: 10.1080/21645515.2021.1875761.